Compare Apple Inc (AAPL) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Citius Pharmaceuticals Inc — how do they compare? Apple Inc trades at $302.21 (market cap $4.45T), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: Apple Inc is far larger — about 222388.8× Citius Pharmaceuticals Inc's market cap, and Apple Inc pays a 0.35% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AAPL | CTXR | |
|---|---|---|
Market Cap | $4.45T | $20.01M |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $1.82 |
52-Week Low | $224.90 | $0.48 |
Enterprise Value | $4.47T | $16.23M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.42, down 2.22% on the day, with a bearish technical signal. The stock shows strong fundamentals, including a 26.91% net income margin and consistent earnings beats. Recent news highlights Apple's leadership in smartphone shipments and AI potential through its 2.5 billion active devices, though it faces challenges from union disputes and potential earnings pressure.
Outlook remains positive with a consensus price target of $337.63, implying 12% upside. Risks include weaker iPhone sales, regulatory scrutiny from EU fines, and competitive pressures. Analyst sentiment is bullish (63.64% buy ratings), but technical weakness and near-term headwinds warrant caution.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
